drugset / Trial / NCT01670890
Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas
Phase 2
Unknown
120 enrolled
Peking Union Medical College Hospital
Beijing Tiantan Hospital · collabTianjin Medical University General Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Temozolomide is the standard adjuvant chemotherapy of newly-diagnosis malignant gliomas.Cisplatin , a kind of chemotherapeutics, can enforce the anti-tumor effects of TMZ. Up to now, the prognosis of recurrent gliomas is very pessimistic and the standard treatment procedure has not been established yet. The prospective,multicentre phase II clinical study is to evaluate the efficacy and safety of TMZ and CDDP in patients with recurrent malignant gliomas
Timeline
- Start
- 2012-08
- Primary completion
- 2014-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 100 mg | Intravenous |
| Comparator | TMZ | Unknown | 50 mg/m2 | Oral |